Physician VersionPatient Version

Protocol No.Principal InvestigatorPhaseAge GroupScopeSecondary Protocol No.Status
OSU-12127Lustberg, MaryamIIAdultNationalCBKM120F2202Open

Adapted from the National Cancer Institute's Physician Data Query (PDQ®) Cancer Clinical Trials (http://www.cancer.gov/clinicaltrials)

Title

A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Summary

This study will evaluate whether the addition of daily BKM120 to weekly paclitaxel is effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.

To view the NCI PDQ information for this trial, click here

To view the clinicaltrials.gov information for this trial, click here

Eligibility

Inclusion Criteria:

Exclusion Criteria:

Applicable Disease Sites

Breast

Participating Institutions

Stephanie Spielman Comprehensive Breast Center

Contact

Clinical Research Spec Katlyn Tolliver
Phone:614-685-6456
Email:Katlyn.Tolliver@osumc.edu